Head-to-head evidence
SYH2053 vs Tafolecimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
SYH2053
Developed by CSPC Pharmaceutical Group
NCT07421232 · Phase 2 · completed
The trial was randomized and participant-blinded, with placebo and inclisiran comparator groups, and enrolled 156 participants. Its primary endpoint was the clinically accepted LDL-C measure, but the outcome comparison cannot yet be assessed because results are not available.
Next expected readout: December 2027 · NCT07421284 (registry estimate)
Tafolecimab · Sintbilo
Marketed by Innovent Biologics
NCT04289285 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial enrolled 804 participants and met its primary endpoint: LDL cholesterol fell by roughly 57 to 65 percentage points more than placebo across both dosing regimens, a highly statistically significant result.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SYH2053's landscape · Tafolecimab's landscape